APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma
Trial Details
- NCT ID
- NCT04657861
- Phase
- EARLY_PHASE1
- Sponsor
- Zhejiang University
- Status
- RECRUITING
- Cancer Type
- Multiple Myeloma
- Interventions
- Locations (sample)
- Hangzhou, Zhejiang, China|30.29365,120.16142
Key Eligibility Criteria
- Histologically confirmed diagnosis of BCMA/TACI+ multiple myeloma (MM)：
- Patients with MM relapsed after BCMA CAR-T therapy; Or MM with positive BCMA/TACI expression;
- Relapsed after hematopoietic stem cell transplantation;
- Cases with recurrent positive minimal residual disease;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Multiple Myeloma Trials on Trialify →